Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.

The IMPULS trial is a randomized, triple-blinded, placebo controlled, single center, pilot trial examining the efficacy and safety of preoperative propranolol in patients scheduled for pancreatic cancer surgery. The study is conducted as a type 1 hybrid efficacy-implementation trial of 30 patients. This study is designed to provide pilot data for a future larger perioperative study of propranolol with the aim of improving outcomes for pancreatic cancer surgery. In total, 30 participants will be allocated in a 1:1 ratio with 15 participants enrolled in each trial arm (propranolol vs. placebo)

Trial Details

NCT ID
NCT06145074
Phase
PHASE2
Sponsor
Zealand University Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Propranolol
  • Placebo
Locations (sample)
  • Copenhagen, Denmark|55.67594,12.56553
  • Køge, Denmark|55.45802,12.18214

Key Eligibility Criteria

  • Patients with suspected surgically resectable pancreatic cancer
  • Indication for surgical treatment with curative intend.
  • Provide written informed consent.
  • Patients minimum 18 years old.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →